|
| 36810256 | SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis. | JCI Insight | 2023 |
| 36973268 | Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. | Nat Commun | 2023 |
| 37198186 | Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. | Nat Commun | 2023 |
| 36810256 | SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis. | JCI Insight | 2023 |
| 36973268 | Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. | Nat Commun | 2023 |
| 37198186 | Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma. | Nat Commun | 2023 |
| 35115713 | SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. | Nat Cancer | 2022 |
| 36288724 | Tumor-associated macrophages expressing the transcription factor IRF8 promote TÂ cell exhaustion in cancer. | Immunity | 2022 |
| 35576438 | Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. | Clin Cancer Res | 2022 |
| 35944503 | Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. | Cancer Cell | 2022 |
| 35977503 | Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity. | Cell Rep | 2022 |
| 35115713 | SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. | Nat Cancer | 2022 |
| 35576438 | Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. | Clin Cancer Res | 2022 |
| 36288724 | Tumor-associated macrophages expressing the transcription factor IRF8 promote TÂ cell exhaustion in cancer. | Immunity | 2022 |
| 35977503 | Multiregional single-cell proteogenomic analysis of ccRCC reveals cytokine drivers of intratumor spatial heterogeneity. | Cell Rep | 2022 |
| 35944503 | Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. | Cancer Cell | 2022 |
| 34088495 | The 2021 Variant Histology Issue. | Clin Genitourin Cancer | 2021 |
| 33784495 | Structural insights into the function of the catalytically active human Taspase1. | Structure | 2021 |
| 34156981 | Taspase1 orchestrates fetal liver hematopoietic stem cell and vertebrae fates by cleaving TFIIA. | JCI Insight | 2021 |
| 33771855 | Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer. | Clin Cancer Res | 2021 |
| 33610279 | The 2021 COVID-19 Artificial Intelligence Issue. | Clin Genitourin Cancer | 2021 |
| 34143969 | Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. | Lancet Oncol | 2021 |
| 33657295 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. | N Engl J Med | 2021 |
| 34088495 | The 2021 Variant Histology Issue. | Clin Genitourin Cancer | 2021 |
| 33867192 | A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. | Eur Urol | 2021 |
| 34316321 | Resource-efficient pooled sequencing expands translational impact in solid tumors. | Kidney Cancer J | 2021 |
| 34389275 | Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma. | Clin Genitourin Cancer | 2021 |
| 34388376 | Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. | Cancer Cell | 2021 |
| 33657295 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. | N Engl J Med | 2021 |
| 33867192 | A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. | Eur Urol | 2021 |
| 33784495 | Structural insights into the function of the catalytically active human Taspase1. | Structure | 2021 |
| 33610279 | The 2021 COVID-19 Artificial Intelligence Issue. | Clin Genitourin Cancer | 2021 |
| 33771855 | Single-cell Spatial Proteomic Revelations on the Multiparametric MRI Heterogeneity of Clinically Significant Prostate Cancer. | Clin Cancer Res | 2021 |
| 34389275 | Diagnostic Utility of RNA-Seq for Evaluation of PD-L1 Expression in Clear Cell Renal Cell Carcinoma. | Clin Genitourin Cancer | 2021 |
| 34388376 | Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. | Cancer Cell | 2021 |
| 34156981 | Taspase1 orchestrates fetal liver hematopoietic stem cell and vertebrae fates by cleaving TFIIA. | JCI Insight | 2021 |
| 34316321 | Resource-efficient pooled sequencing expands translational impact in solid tumors. | Kidney Cancer J | 2021 |
| 34143969 | Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. | Lancet Oncol | 2021 |
| 32291161 | The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy. | Clin Genitourin Cancer | 2020 |
| 32130964 | The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age. | Semin Nephrol | 2020 |
| 31959902 | Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. | Sci Rep | 2020 |
| 32417157 | Elective Cytoreductive Nephrectomy After Checkpoint Inhibitor Immunotherapy in Patients With Initially Unresectable Metastatic Clear Cell Renal Cell Carcinoma. | Clin Genitourin Cancer | 2020 |
| 32291161 | The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy. | Clin Genitourin Cancer | 2020 |
| 31923397 | Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. | Cell | 2020 |
| 32332851 | Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. | Nat Commun | 2020 |
| 32273127 | The Gender Issue. | Clin Genitourin Cancer | 2020 |
| 32768132 | The 2020 Kidney Cancer Treatment Sequence Issue. | Clin Genitourin Cancer | 2020 |
| 32534803 | The 2020 Bladder Cancer Discrepancy Issue. | Clin Genitourin Cancer | 2020 |
| 33308691 | The 2020 nccRCC Immunotherapy Issue. | Clin Genitourin Cancer | 2020 |
| 33195887 | The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. | Kidney Cancer | 2020 |